Breast-conserving Therapy May be a Treatment Option for Some Patients with Multiple Breast Lesions
SAN ANTONIO – Patients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy...
Search/Filter
Loading...
Genetic Profiling May Identify Patients with Breast Cancer Who Can Safely Omit Radiation Therapy After Breast-conserving Surgery
SAN ANTONIO – Patients with invasive breast cancer who had low scores on an investigational gene molecular signature had...
Camizestrant May Be Superior to Fulvestrant in Patients With Hormone Receptor-positive, HER2-negative Breast Cancer
SAN ANTONIO – The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compared with fulvestrant (Faslodex), in...
Adding Capivasertib to Fulvestrant Improves Progression-free Survival in Patients With Advanced Hormone Receptor-positive Breast Cancer
SAN ANTONIO – In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational...
Treatment Decision Guided by Circulating Tumor Cell Count May Improve Long-term Outcomes for Patients with Metastatic Breast Cancer
SAN ANTONIO – The use of circulating tumor cell (CTC) count to guide the choice between chemotherapy and endocrine...
Breast Cancer Patients Who Interrupted Endocrine Therapy to Pursue Pregnancy Did Not Experience Worse Short-term Recurrence Rates
Most were able to conceive and more than 60 percent gave birth SAN ANTONIO – Breast cancer patients who...
T-DXd Yields Superior Outcomes Over Chemotherapy-based Regimens in Patients Previously Treated with T-DM1
SAN ANTONIO – Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in...
T-DXd Yields Longer Overall Survival than T-DM1 in Patients with HER2-positive Metastatic Breast Cancer
SAN ANTONIO – Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine...
Neoadjuvant Trastuzumab Deruxtecan Shows Clinical Activity in Patients With HER2-low Breast Cancer
SAN ANTONIO – Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the...
Black Women With Breast Cancer May Have Worse Outcomes Than Peers Despite Similar Genetic Recurrence Scores
SAN ANTONIO – Non-Hispanic Black women with hormone receptor (HR)-positive/HER2-negative, lymph node-positive breast cancer had worse outcomes compared to...